Our partners

Ipsen has a long-standing history of successful partnerships with numerous organizations.

Recent partnerships and acquisitions

  • March 8, 2016 Ipsen announced a research partnership with Peptimimesis, a French start-up from a spin-off project of Strasbourg University and INSERM, the French national institute of health and medical research, to develop novel therapeutic peptides targeting a transmembrane receptor, which is overexpressed in a large number of cancers and is implicated in their development.
  • March 1, 2016 Ipsen bolstered its oncology pipeline by acquiring the rights outside the US, Canada and Japan to Exelixis’ cabozantinib, a treatment today for medullary thyroid cancer and intended for advanced renal cell carcinoma with survival impact for patients.
  • February 17, 2016: Ipsen strengthened its pipeline in niche indication by in-licensing novel radiopharmaceuticals from 3B Pharmaceuticals targeting a neurotensin receptor for the treatment of pancreatic adenocarcinoma.
  • Acquisition of OctreoPharm Sciences in 2015, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours.
  • Option agreement in 2015 to acquire Canbex Therapeutics, a spin-out of University College London (UCL) upon completion of the phase IIa study of Canbex’s lead candidate VSN16R, indicated for spasticity in people with multiple sclerosis.
  • Agreement with Actavis to distribute and promote Eziclen®  / Izinova®  (BLI-800) in the G5 countries (France, Germany, Italy, UK and Spain). In 2009, had acquired exclusive manufacturing, marketing and distribution rights of Braintree’s BLI-800 Eziclen®  / Izinova®  for countries including Europe, CIS and China.
  • In 2015, Ipsen expanded its ties to Harvard University by signing a new Research Alliance Agreement.
  • Commercialization agreement with Lexicon Pharmaceuticals Inc. in 2014 to market Telotristat etiprate outside North America and Japan with a focus on carcinoid syndrome. It was extended to Canada in March 2015.
  • In 2014, Ipsen out-licensed patents, licenses know-how and data to Chinese Peptide Company for research in peptide programs.
  • Licensing agreement with Otonomy Inc. in 2014 enabling Otonomy to utilize Ipsen’s gacyclidine data in the development of OTO-311 for the treatment of tinnitus.
  • Promotion and distribution agreement with GW Pharma for their product Sativex® intended for the treatment of spasticity due to multiple sclerosis, in Latin America (excluding Mexico and the Caribbean).
  • In 2013 Ipsen acquired Syntaxin in the UK, a leading toxin-research company. In the same year a research deal was signed with Harvard Medical School, both creating an expanded toxin environment for research and development for innovative toxins.

Early stage academic partners

  • A*STAR P53LAB (Singapore)
  • Brigham and Women’s Hospital, Boston (USA)
  • Charité Medical School and Hospital, Berlin (Germany)
  • G.B. Rossi Clinic, Verona (Italy)
  • Hanover Medical School (Germany)
  • Harvard Medical School (USA)
  • Hôpital Saint-Antoine (France)
  • Hôpital Pierre Wertheimer (France)
  • INSERM (France)
  • Institut du Cerveau et de la Moëlle Épinière (France)
  • Institut Curie (France)
  • Institut Gustave Roussy, Paris (France)
  • Lund University, Malmö (Sweden)
  • Massachusetts General Hospital, Boston (USA)
  • Salk Institute, San Diego (USA)
  • SNCC (Singapore)
  • University of Cordoba (Spain)
  • University of Genoa (Italy)
  • University of Lund, Malmö (Sweden)
  • University of Rome (Italy)
  • University of Strasbourg (France)
  • University Hospital, Uppsala (Sweden)
Updated on 02 June 2016